Co-Diagnostics Expands Distribution to Four Countries, Accessing $13B Market
Co-Diagnostics' Indian JV CoSara Diagnostics has agreed to expand CoSara PCR Pro and SARAGENE distribution to Bangladesh, Pakistan, Nepal and Sri Lanka, increasing its addressable market to $13.0 billion. This expansion supports planned regulatory approval and commercialization of its molecular diagnostics platforms across South Asia.
1. Expansion Agreement
CoSara Diagnostics, the Indian joint venture of Co-Diagnostics, has signed agreements to extend its commercial and distribution rights for the CoSara PCR Pro point-of-care platform and SARAGENE product line to Bangladesh, Pakistan, Nepal and Sri Lanka.
2. Market Opportunity
This territorial expansion increases the potential customer base to an estimated $13.0 billion across South Asia, marking a substantial increase in addressable market for Co-Diagnostics’ molecular diagnostics solutions.
3. Next Steps and Timeline
Pending necessary regulatory approvals in each country, CoSara Diagnostics plans to begin commercialization and deployment of its PCR-based diagnostic platforms, with distribution channels being established to support regional rollouts.